Global Acute Bronchitis Market – Industry Trends and Forecast to 2029

Global Acute Bronchitis Market, By Type (Viral Infection, Bacterial Infection, Irritants, Others), Treatment (Homecare, Medication, Others), Route of Administration (Oral, Parenteral Inhalational, Others), End-Users (Hospitals, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others) – Industry Trends and Forecast to 2029.

Acute Bronchitis Market Analysis and Size

The global acute bronchitis market is expected to witness significant growth during the forecast period. Increasing allergic reactions worldwide and the emerging markets are the factors responsible for the growth of this market. Growing cases of common cold and flu which causes coughing problem drives the acute bronchitis market. Maximum cases of acute bronchitis are caused due to viruses and the most common symptom of acute bronchitis is cough.

Data Bridge Market Research analyses a growth rate in the global acute bronchitis market in the forecast period 2022-2029. The expected CAGR of global acute bronchitis market is tend to be around 4.0% in the mentioned forecast period. The market was valued at USD 4.0 billion in 2021, and it would grow upto USD 5.47 billion by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Market Definition

Acute bronchitis is the bronchial tube inflammation that connects with the trachea and carries air into the lungs. This inflammation can be caused by viral or bacterial infection. The initial symptoms are common cold or flu that spreads from nose and throat down into the airways. The infection can stay for two weeks and the mild cases can be treated at home itself.

Acute Bronchitis Market Scope and Segmentation

Global Acute Bronchitis Market Dynamics

Drivers

• Increasing Prevalence of COPD

Rising prevalence of COPD is a major factor boosting the market growth. As per WHO 2021, COPD is the third leading cause of death worldwide, causing 3.23 million deaths in 2019. Thus, it is increasing the demand for acute bronchitis treatment.

• Growing Demand for bronchodilators

The bronchodilator segment is expected to boost the market growth. Bronchodilators are the first-line medication for bronchitis treatment as it helps in clearing airway obstruction, which is an essential parameter in acute bronchitis to ease the breathing process in patients.

Opportunities

• Rising Prevalence of Smoking

Smoking is the leading cause of preventable disease in the U.S., witnessing more than 480,000 deaths yearly, or about 1 in 5 deaths. Currently, cigarette smoking is highest among people aged 25–44 and 45–64. Thus, it creates opportunities for market growth.

• Advanced Clinical Research and Innovative Strategies

Several market players are engaged in the implementation of strategic initiatives, thereby contributing to market growth. For instance, Beta2-agonists was developed because clinicians suspect many patients also have reversible airflow restriction (as seen in asthma or chronic obstructive pulmonary disease (COPD)) contributing to the symptoms.

Restraints/Challenges

• Lack of Awareness

Lack of patient awareness about the disease and differentiated symptoms could curb the growth of the global acute bronchitis market over a forecast period.

• High Cost

The huge expenditure required for treating acute bronchitis surely hamper the market growth.

This global acute bronchitis market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global acute bronchitis market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Acute Bronchitis Market

Considering the present scenario, COVID-19 has left a major global public health crisis impacting every business. Its long-term repercussions are expected to influence industry growth during the forecast period.

The initial phase of the COVID-19 pandemic has led to a reduction in the number of patient visits that reduced the number of patients opting for bronchitis treatment, thereby impacting the market growth. The pandemic has led to an overall reduction in ambulatory adults seeking care for bronchitis in the health system and has resulted in a dramatic reduction in antibiotic prescriptions for this disease.  

Global Acute Bronchitis Market Scope

The global acute bronchitis market is segmented on the basis of type, treatment, route of administration, end-user and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Viral Infection
• Bacterial Infection
• Irritants
• Others

Treatment

• Homecare
• Medication
• Others

Route of Administration

• Oral
• Parenteral Inhalational
• Others

End-Users

• Hospitals
• Specialty Clinics
• Others

Distribution Channel

• Hospitals
• Specialty Clinics
• Others

Acute Bronchitis Market Regional Analysis/Insights

The global acute bronchitis market is analysed and market size insights and trends are provided by type, treatment, route of administration, end-user and distribution channel as referenced above.

The major countries covered in the global acute bronchitis market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is the dominating region due to rising infection in children & elderly population, and rising initiatives taken by the pharmaceutical organizations.

Asia-Pacific is likely to hold the largest market share for the acute bronchitis market due to more initiatives taken by the government organizations to spread awareness and immense presence of generic manufacturers. 

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Acute Bronchitis Market Share Analysis

The global acute bronchitis market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global acute bronchitis market

Key players operating in the global acute bronchitis market include:

• Bayer AG (Germany)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Sun Pharmaceutical Industries Ltd. (India)
• Hikma Pharmaceutical PLC (U.S.)
• Amneal Pharmaceuticals LLC. (U.K.)
• Aurobindo Pharma (India)
• Johnsons & Johnsons Services,Inc (U.S.)
• GlaxoSmithKline Plc (U.S.)